Academy Capital Management Acquires 1,781 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Academy Capital Management boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,794 shares of the company's stock after buying an additional 1,781 shares during the quarter. IDEXX Laboratories makes up about 2.6% of Academy Capital Management's investment portfolio, making the stock its 12th largest position. Academy Capital Management's holdings in IDEXX Laboratories were worth $15,032,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of IDXX. GAMMA Investing LLC boosted its stake in IDEXX Laboratories by 59,810.7% in the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock valued at $3,856,950,000 after buying an additional 916,898 shares in the last quarter. Nuveen LLC acquired a new stake in IDEXX Laboratories in the 1st quarter valued at $179,784,000. Principal Financial Group Inc. boosted its stake in IDEXX Laboratories by 58.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock valued at $472,865,000 after buying an additional 414,802 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in IDEXX Laboratories in the 4th quarter valued at $156,412,000. Finally, BNP Paribas Financial Markets boosted its stake in IDEXX Laboratories by 221.3% in the 4th quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock valued at $182,459,000 after buying an additional 303,966 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Michael Lane sold 8,411 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the sale, the executive vice president owned 7,132 shares in the company, valued at approximately $4,477,041.68. This represents a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael G. Erickson sold 406 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president owned 11,287 shares in the company, valued at $7,336,098.52. The trade was a 3.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,870 shares of company stock valued at $32,877,757 in the last ninety days. Insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on IDXX shares. Morgan Stanley boosted their price target on IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a research note on Friday, August 15th. JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research report on Monday, August 4th. BTIG Research lifted their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Leerink Partners lifted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Finally, Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $649.44.

IDEXX Laboratories Stock Up 2.0%

Shares of IDXX stock traded up $12.50 on Friday, hitting $645.55. 352,260 shares of the stock were exchanged, compared to its average volume of 829,808. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $51.64 billion, a P/E ratio of 53.75, a price-to-earnings-growth ratio of 4.10 and a beta of 1.49. The business has a 50-day moving average of $569.94 and a 200 day moving average of $493.97. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the company posted $2.44 earnings per share. IDEXX Laboratories's revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.